Cagrilintide (5 mg) + Semaglutide (5 mg) | GLP-1 Weight Management Blend | COA Verified
Product Details
CAGRISEMA is a dual-peptide research blend combining Cagrilintide (amylin analog) and Semaglutide (GLP-1 receptor agonist), widely studied for its role in appetite regulation signaling, metabolic efficiency pathways, and glucose homeostasis mechanisms. This synergistic formulation is a key compound of interest in research focused on energy balance, nutrient utilization, and body composition regulation.
CAGRISEMA is frequently investigated in studies exploring satiety signaling, insulin response pathways, lipid metabolism, and metabolic adaptation, supporting advanced exploration of weight management and metabolic wellness physiology.
Product Highlights
-
Dual-peptide metabolic regulation research blend
-
Combines amylin and GLP-1 pathway signaling mechanisms
-
Studied for appetite regulation and satiety signaling
-
Supports metabolic efficiency and energy balance research
-
Investigated in glucose regulation and lipid metabolism pathways
-
Research-grade peptide formulation
Specifications
| Brand | |
|---|---|
| MAL Number | |
| Series | |
| Model | |
| SKU | |
| Product Form | |
| Ingredients | |
| Pack Type | |
| Net Content | |
| Days of Supply | |
| Recommended User | |
| Usage Instructions | |
| Storage Instructions | |
| Warranty Type |
Potential Health & Wellness Benefits
Quality Assurance
Why Choose Elite Bio Compounds?
Product Includes: